Tag: cannabis
-
![Revive (RVV.C) stock ramps hard on news from a collaborator]()
Revive (RVV.C) stock ramps hard on news from a collaborator
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”.
-
![Harborside (HBOR.C) reports good Q3, 2020 financial results]()
Harborside (HBOR.C) reports good Q3, 2020 financial results
During Q3 2020, Harborside generated total gross revenues of approximately $19.6 million, representing a 21.2% sequential growth over Q2, 2020
-
![Revive (RVV.C) advances mushroom bio-tech as new regs change the game]()
Revive (RVV.C) advances mushroom bio-tech as new regs change the game
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison”. RVV is a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders.…
-
Pure Extracts (PULL.C) goes public with profit-focused cannabis (and mushroom) extraction business model
Yeah, I know, I know. Canadian cannabis companies are ass right now, and have been for a few years. Trust me, I’m about as out of the LP business now as I’ve ever been, but you’d also be an idiot to tar every cannabis company with the same brush, because not every deal involves growing…
-
![Harborside (HBOR.C) upgrades California grow-op, launches clone sales, pushes rev. projections higher]()
Harborside (HBOR.C) upgrades California grow-op, launches clone sales, pushes rev. projections higher
The company’s in-house brand, Harborside Farms will begin sales of clones grown at its Salinas facility at all Harborside branded locations, including Desert Hot Springs.
-
![Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms]()
Xphyto (XPHY.C) targets industrial manufacture of psilocybin as U.S. voters weigh in on mushrooms
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised.
-
Revive Therapeutics (RVV.C) to have 10 clinical COVID-19 FDA trial sites by end of year
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the thought that a three time loser might be relevant in 2020. Having missed on an earlier pharma focus, and come to the cannabis party a little…
-
Harborside (HBOR.C) adds to San Francisco dispensary portfolio
On October 19, 2020 Harborside (HBOR.C) announced that it has reached a definitive agreement to acquire 50.1% of FGW Haight – a California co. that has the “conditional-use approval” to operate a cannabis dispensary and related businesses in the iconic Haight Ashbury area of San Francisco, Calif.
-
![Heritage Cannabis (CANN.C) granted oil sales licence – CannaCure’s Fort Erie facility in focus]()
Heritage Cannabis (CANN.C) granted oil sales licence – CannaCure’s Fort Erie facility in focus
CannaCure’s goal is “to transform the global marijuana landscape through innovative growth strategies and strategic partnerships with manufacturers of cannabis products.”
-
Harborside (HBOR.C) – a U.S.-based cash-generating community-minded cannabis business
Last quarter’s gross revenue was 73% of the company’s current market cap.
